Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic...

Antidiabetics Market – Global Industry Analysis Report, Size, Share, Growth, Price Trends and Forecast, 2023: Fractovia.org Ocean View, Delaware, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Antidiabetics market is anticipated to surpass USD 116 billion revenue by 2023 owing to the alarming diabetes occurrence rate worldwide....